581 related articles for article (PubMed ID: 20045290)
1. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
[TBL] [Abstract][Full Text] [Related]
2. Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-nonsusceptible Pseudomonas aeruginosa.
Ray GT; Baxter R; DeLorenze GN
Clin Infect Dis; 2005 Aug; 41(4):441-9. PubMed ID: 16028150
[TBL] [Abstract][Full Text] [Related]
3. Fluoroquinolone-resistant Pseudomonas aeruginosa in chronic rhinosinusitis.
Guss J; Abuzeid WM; Doghramji L; Edelstein PH; Chiu AG
ORL J Otorhinolaryngol Relat Spec; 2009; 71(5):263-7. PubMed ID: 19797934
[TBL] [Abstract][Full Text] [Related]
4. Correlation between fluoroquinolone consumption in hospitals and ciprofloxacin resistance amongst Pseudomonas aeruginosa isolates causing healthcare-associated infections, Taiwan, 2000-2009.
Weng TC; Chen YH; Lee CC; Wang CY; Lai CC; Tang HJ; Ko WC; Hsueh PR
Int J Antimicrob Agents; 2011 Jun; 37(6):581-4. PubMed ID: 21489757
[No Abstract] [Full Text] [Related]
5. Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa.
Muramatsu H; Horii T; Takeshita A; Hashimoto H; Maekawa M
Chemotherapy; 2005 May; 51(2-3):70-5. PubMed ID: 15870499
[TBL] [Abstract][Full Text] [Related]
6. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities.
Polk RE; Johnson CK; McClish D; Wenzel RP; Edmond MB
Clin Infect Dis; 2004 Aug; 39(4):497-503. PubMed ID: 15356812
[TBL] [Abstract][Full Text] [Related]
7. In vitro fluoroquinolone susceptibility of Pseudomonas aeruginosa isolates from dogs with ulcerative keratitis.
Ledbetter EC; Hendricks LM; Riis RC; Scarlett JM
Am J Vet Res; 2007 Jun; 68(6):638-42. PubMed ID: 17542697
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa.
Paladino JA; Sunderlin JL; Forrest A; Schentag JJ
J Antimicrob Chemother; 2003 Sep; 52(3):457-63. PubMed ID: 12888598
[TBL] [Abstract][Full Text] [Related]
9. Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience.
Tennenberg AM; Davis NB; Wu SC; Kahn J
Curr Med Res Opin; 2006 May; 22(5):843-50. PubMed ID: 16709306
[TBL] [Abstract][Full Text] [Related]
10. [Susceptibility of 570 Pseudomonas aeruginosa strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones].
Lei YC; Wang HB; Sun ZY; Shen ZY
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):403-7. PubMed ID: 12820918
[TBL] [Abstract][Full Text] [Related]
11. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Roveta S; Schito AM; Marchese A; Schito GC
Int J Antimicrob Agents; 2005 Nov; 26(5):366-72. PubMed ID: 16216467
[TBL] [Abstract][Full Text] [Related]
12. Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private, university-affiliated teaching hospital: an 8-year-experience: 1995-2002.
Mohr JF; Jones A; Ostrosky-Zeichner L; Wanger A; Tillotson G
Int J Antimicrob Agents; 2004 Oct; 24(4):346-51. PubMed ID: 15380259
[TBL] [Abstract][Full Text] [Related]
13. Induction of resistance to fluoroquinolones in clinical and environmental isolates of Pseudomonas aeruginosa.
Prasad SV; Ballal M; Shivananda PG
Indian J Pathol Microbiol; 2007 Jan; 50(1):94-6. PubMed ID: 17474274
[TBL] [Abstract][Full Text] [Related]
14. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
Master RN; Clark RB; Karlowsky JA; Ramirez J; Bordon JM
Int J Antimicrob Agents; 2011 Oct; 38(4):291-5. PubMed ID: 21737249
[TBL] [Abstract][Full Text] [Related]
15. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
[TBL] [Abstract][Full Text] [Related]
16. Comparison of in vitro activities of levofloxacin, ciprofloxacin, ceftazidime, cefepime, imipenem, and piperacillin-tazobactam against aerobic bacterial pathogens from patients with nosocomial infections.
Huang SS; Lee SC; Lee N; See LC; Tsai MH; Shieh WB
J Microbiol Immunol Infect; 2007 Apr; 40(2):134-40. PubMed ID: 17446961
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001).
Mutnick AH; Rhomberg PR; Sader HS; Jones RN
J Antimicrob Chemother; 2004 Feb; 53(2):290-6. PubMed ID: 14711839
[TBL] [Abstract][Full Text] [Related]
18. The impact of fluoroquinolones use on antibiotic resistance in an intensive care burn department.
Thabet L; Memmi M; Turki A; Messadi AA
Tunis Med; 2010 May; 88(5):297-300. PubMed ID: 20517823
[TBL] [Abstract][Full Text] [Related]
19. Reduction of fluoroquinolone use is associated with a decrease in methicillin-resistant Staphylococcus aureus and fluoroquinolone-resistant Pseudomonas aeruginosa isolation rates: a 10 year study.
Lafaurie M; Porcher R; Donay JL; Touratier S; Molina JM
J Antimicrob Chemother; 2012 Apr; 67(4):1010-5. PubMed ID: 22240401
[TBL] [Abstract][Full Text] [Related]
20. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
